Cost-Effectiveness of Combination Amivantamab–Lazertinib, Osimertinib Plus Chemotherapy, and Osimertinib Monotherapy in Lung Cancer

JNCCN Journal of the National Comprehensive Cancer Network · Published 2026-07-16 · DOI 10.6004/jnccn.2026.7017

Authors (4)

Jui-Hung Tsai, Sheng-Han Tsai, Li-Jun Chen, Szu-Chun Yang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Tsai, J., Tsai, S., Chen, L., et al. (2026). Cost-Effectiveness of Combination Amivantamab–Lazertinib, Osimertinib Plus Chemotherapy, and Osimertinib Monotherapy in Lung Cancer. JNCCN Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2026.7017

Related articles